HER2-negative

Beyond's analysis on HER2-negative

• 2026-09-01 — Kazia Therapeutics widens Paxalisib trial to HR+/HER2- breast cancer based on promising preclinical data
• 2026-08-25 — Astellas initiates Phase 3 trial of ASP2138 for CLDN18.2-positive gastric cancer, advancing its oncology pipeline

Recent news mentioning HER2-negative

• 2026-08-24 — Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Appears alongside

• Astellas Doses First Patient
• Phase
• Study
• ASP2138
• CLDN18.2-postive

Browse the full archive →